Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019024635) 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/024635 International Application No.: PCT/CN2018/093760
Publication Date: 07.02.2019 International Filing Date: 29.06.2018
IPC:
C07D 307/78 (2006.01) ,C07D 277/62 (2006.01) ,C07D 317/46 (2006.01) ,C07D 327/04 (2006.01) ,A61K 31/381 (2006.01) ,A61P 3/00 (2006.01) ,A61P 3/08 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
307
Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
77
ortho- or peri-condensed with carbocyclic rings or ring systems
78
Benzo [b] furans; Hydrogenated benzo [b] furans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
277
Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
60
condensed with carbocyclic rings or ring systems
62
Benzothiazoles
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
317
Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
08
having the hetero atoms in positions 1 and 3
44
ortho- or peri-condensed with carbocyclic rings or ring systems
46
condensed with one six-membered ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
327
Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
02
one oxygen atom and one sulfur atom
04
Five-membered rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
38
having sulfur as a ring hetero atom
381
having five-membered rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
Applicants:
广州必贝特医药技术有限公司 GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. [CN/CN]; 中国广东省广州市 高新技术产业开发区科学城崖鹰石路25号A-3栋第8层802房 Room 802, 8th Floor, Building A-3, No. 25 Yayingshi Road, Science City, High-Tech Industrial Development Zone, Guangzhou, Guangdong 510660, CN
Inventors:
蔡雄 CAI, Xiong; CN
钱长庚 QIAN, Changgeng; CN
叶春强 YE, Chunqiang; CN
何其捷 HE, Qijie; CN
Agent:
广州华进联合专利商标代理有限公司 ADVANCE CHINA IP LAW OFFICE; 中国广东省广州市 天河区花城大道85号3901房 Room 3901, No. 85 Huacheng Avenue Tianhe District, Guangzhou Guangdong 510623, CN
Priority Data:
201710643304.331.07.2017CN
201810629882.619.06.2018CN
Title (EN) 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF
(FR) COMPOSÉ CÉTÈNE 1,3-DI-SUBSTITUÉ ET SON APPLICATION
(ZH) 1,3-二取代烯酮类化合物及其应用
Abstract:
(EN) Provided are a 1,3-di-substituted ketene compound having a structure as represented by formula (I) and an application thereof. Such a type of compound primarily activates peroxisome proliferator-activated receptor (PPAR) α, and also activates PPPAδ and PPPAγ. The compound may be used to treat various diseases associated with PPAR regulation and control abnormality, such as non-alcoholic fatty liver disease, and especially in treating non-alcoholic hepatitis, and may potentially be used in the treatment of diseases comprising diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising heart failure, atherosclerosis, and so on), kidney diseases (comprising chronic kidney disease, renal failure, and so on), and brain degenerative diseases (comprising Alzheimer's disease and so on), having great application value.
(FR) L'invention concerne un composé cétène 1,3-di-substitué ayant une structure telle que représentée par la formule (I) et une application de celui-ci. Un tel type de composé active principalement le récepteur α activé par les proliférateurs des peroxysomes (PPAR), et active également PPPAδ et PPPAγ. Le composé peut être utilisé pour traiter diverses maladies associées à la régulation de PPAR et à une anomalie de commande, telle qu'une stéato-hépatopathie non alcoolique, et en particulier dans le traitement de l'hépatite non alcoolique, et peut potentiellement être utilisé dans le traitement de maladies notamment le diabète, l'obésité, des maladies fibrotiques, des maladies cardiovasculaires (y compris l'insuffisance cardiaque, l'athérosclérose, etc.), des maladies rénales (y compris la maladie rénale chronique, l'insuffisance rénale, etc.), et des maladies dégénératives du cerveau (y compris la maladie d'Alzheimer, etc.), ayant une grande valeur d'application.
(ZH) 提供一种具有式(I)所示结构的1,3-二取代烯酮类化合物及其应用。该类化合物主要激活PPARα,对PPPAδ和PPPAγ亦有激动活性。能够用于治疗PPAR调控异常相关的各种疾病,如非酒精性脂肪肝病特别是治疗非酒精性肝炎,还具有用于治疗糖尿病、肥胖症、纤维化疾病、心血管疾病(包括心力衰竭和动脉粥样硬化等)、肾脏疾病(包括慢性肾病和肾功能衰竭等)、脑退行性疾病(包括阿尔茨海默病等)等的潜力,具有较大的应用价值。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)